Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy
Robert C. Sterner, Rosalie M. Sterner
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 50

Showing 1-25 of 50 citing articles:

Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network
Heinz Ludwig, Evangelos Terpos, Niels W.C.J. van de Donk, et al.
The Lancet Oncology (2023) Vol. 24, Iss. 6, pp. e255-e269
Open Access | Times Cited: 85
Enhancing the safety of CAR-T cell therapy: Synthetic genetic switch for spatiotemporal control
Li Lu, Mingqi Xie, Bo Yang, et al.
Science Advances (2024) Vol. 10, Iss. 8
Open Access | Times Cited: 19
CAR T-cell-associated neurotoxicity in central nervous system hematologic disease: Is it still a concern?
Roser Velasco, Alberto Mussetti, Macarena Villagrán‐García, et al.
Frontiers in Neurology (2023) Vol. 14
Open Access | Times Cited: 26
Current and emerging pharmacotherapies for cytokine release syndrome, neurotoxicity, and hemophagocytic lymphohistiocytosis-like syndrome due to CAR T cell therapy
Zandra E. Walton, Matthew J. Frigault, Marcela V. Maus
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 3, pp. 263-279
Closed Access | Times Cited: 9
Targeting TGFβ-activated kinase-1 activation in microglia reduces CAR T immune effector cell-associated neurotoxicity syndrome
Janaki Manoja Vinnakota, Francesca Biavasco, Marius Schwabenland, et al.
Nature Cancer (2024) Vol. 5, Iss. 8, pp. 1227-1249
Closed Access | Times Cited: 9
Toxicity Profile of Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapies in Multiple Myeloma: Pathogenesis, Prevention and Management
Mariam Markouli, Fauzia Ullah, Serhan Ünlü, et al.
Current Oncology (2023) Vol. 30, Iss. 7, pp. 6330-6352
Open Access | Times Cited: 21
CAR-T State of the Art and Future Challenges, A Regulatory Perspective
Lorenzo Giorgioni, Alessandra Ambrosone, Maria Francesca Cometa, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 14, pp. 11803-11803
Open Access | Times Cited: 19
Neoantigen-directed therapeutics in the clinic: where are we?
Lien Lybaert, Kris Thielemans, Steven A. Feldman, et al.
Trends in cancer (2023) Vol. 9, Iss. 6, pp. 503-519
Open Access | Times Cited: 16
CAR-T Cell Therapy in Ovarian Cancer: Where Are We Now?
Clare Cutri‐French, Dimitrios Nasioudis, Erin George, et al.
Diagnostics (2024) Vol. 14, Iss. 8, pp. 819-819
Open Access | Times Cited: 7
Recent Updates on Chimeric Antigen Receptor T-Cell Approaches in Cancer Immunotherapy
Maryam Sahlolbei, Amirhossein Ahmadieh-Yazdi, Mohadeseh Rostamipoor, et al.
IntechOpen eBooks (2024)
Open Access | Times Cited: 5
Universal CAR 2.0 to overcome current limitations in CAR therapy
Lara Sophie Schlegel, Coralie Werbrouck, Michael Boettcher, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 5
New developments in immunotherapy for SCLC
Tsering Dolkar, Christopher Gates, Zhonglin Hao, et al.
Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 1, pp. e009667-e009667
Open Access
The Role of Electroencephalography Following CAR-T Cell Therapy in Clinical Practice
A.J. Matthews, Fiona E Starkie, Lydia E Staniaszek, et al.
Clinical EEG and Neuroscience (2025)
Closed Access
Implementation of chimeric antigen receptor (CAR) T-cell therapy in the NHS: prospects, promises and pitfalls
Ruff Joseph Macale Cajanding
British Journal of Nursing (2025) Vol. 34, Iss. 5, pp. S20-S30
Closed Access
Advances in Gene Therapy with Oncolytic Viruses and CAR-T Cells and Therapy-Related Groups
Yasunari Matsuzaka, Ryu Yashiro
Current Issues in Molecular Biology (2025) Vol. 47, Iss. 4, pp. 268-268
Open Access
Neurological Complications of Conventional and Novel Anticancer Treatments
Paola Alberti, Alessandro Salvalaggio, Andreas A. Argyriou, et al.
Cancers (2022) Vol. 14, Iss. 24, pp. 6088-6088
Open Access | Times Cited: 21
Reeling in complement in transplant‐associated thrombotic microangiopathy: You're going to need a bigger boat
Sonata Jodele, Anthony Sabulski
American Journal of Hematology (2023) Vol. 98, Iss. S4
Open Access | Times Cited: 11
Charting new paradigms for CAR-T cell therapy beyond current Achilles heels
Ying Li, Zhenhua Hu, Yuanyuan Li, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 4
The Development and Application of Bispecific Antibodies in B-Cell Non-Hodgkin Lymphoma
Laura Sun, Jason T. Romancik
Journal of Personalized Medicine (2025) Vol. 15, Iss. 2, pp. 51-51
Open Access
New approach methodologies to assess wanted and unwanted drugs-induced immunostimulation
Valeria Bettinsoli, Gloria Melzi, I. Marchese, et al.
Current Research in Toxicology (2025) Vol. 8, pp. 100222-100222
Open Access
Exosomes in review: A new frontier in CAR-T cell therapies
Jiguang Wang, Samuel J Schellenberg, Athena Demeros, et al.
Neoplasia (2025) Vol. 62, pp. 101147-101147
Closed Access
Principles of Immunotherapy and Novel Immunotherapeutic Agents for Pediatric Cancer Management
Zachary Morrison, Ali Suliman
(2025), pp. 1-12
Closed Access
Anticancer activity of combination targeted therapy using cetuximab plus vemurafenib for refractory BRAFV600E-mutant metastatic colorectal carcinoma
K. Connolly, Daniel Brungs, E. Szeto, et al.
Current Oncology (2013) Vol. 21, Iss. 1, pp. 151-151
Open Access | Times Cited: 41
Fine-tuning the antigen sensitivity of CAR T cells: emerging strategies and current challenges
Dennis Christoph Harrer, Sin‐Syue Li, Marcell Kaljanac, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 9
Brief research report: in-depth immunophenotyping reveals stability of CD19 CAR T-cells over time
Ivan Odak, Lâle M. Bayir, Lennart Riemann, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top